Top

Published in:

01-02-2019 | Review Article

Treating early-stage myelofibrosis

Authors: Francesca Palandri, Elena Sabattini, Margherita Maffioli

Published in: Annals of Hematology | Issue 2/2019

Abstract

Myelofibrosis (MF) is a Philadelphia chromosome–negative myeloproliferative neoplasm associated with bone marrow fibrosis, splenomegaly, a high symptom burden, and poor prognosis. Treatment is based on a risk-adapted approach, with treatment guidelines generally recommending allogeneic stem cell transplant or drug-based therapy for patients with higher-risk or more advanced disease and recommending observation or the “watch-and-wait” strategy for those with lower-risk or early-stage MF. With the advent of targeted therapies, such as the Janus kinase inhibitors, many patients have experienced substantial clinical benefits, including reduction in splenomegaly and symptoms and, in some instances, improvement or stabilization of bone marrow fibrosis and reduction of JAK2 V617F allele burden. These observations raise the possibility of patients in earlier phases of the disease also benefiting from treatment with targeted therapies. In this review, we discuss the current treatment options for patients with early-stage MF and the available evidence supporting the treatment of patients with less-advanced disease. Overall, therapies used to treat patients with early-stage MF will have to be assessed in randomized studies, with the potential benefits balanced against adverse events associated with treatment.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405. https://doi.org/10.1182/blood-2016-03-643544 CrossRefPubMed

Cervantes F (2014) How I treat myelofibrosis. Blood 124:2635–2642. https://doi.org/10.1182/blood-2014-07-575373 CrossRefPubMed

Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895–2901. https://doi.org/10.1182/blood-2008-07-170449 CrossRefPubMed

Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, Tefferi A (2010) Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 116:2857–2858. https://doi.org/10.1182/blood-2010-06-293415 CrossRefPubMed

Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392–397. https://doi.org/10.1200/JCO.2010.32.2446 CrossRefPubMed

Vannucchi AM, Guglielmelli P, Rotunno G et al (2014) Mutation-Enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project. Blood 124:abstract 405

Guglielmelli P, Lasho TL, Rotunno G et al (2018) MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol 35:310–318. https://doi.org/10.1200/JCO.2017.76.4886 CrossRef

Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, de Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM (2017) A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 31:2726–2731. https://doi.org/10.1038/leu.2017.169 CrossRefPubMed

Barosi G (2014) Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter. Best Pract Res Clin Haematol 27:129–140. https://doi.org/10.1016/j.beha.2014.07.004 CrossRefPubMed

10.

Gong X, Lu X, Xiao X, Wang W, Yang J, Fu Y, Zheng Y, Tang Q, Zhang X (2014) Clinicopathologic characteristics of prefibrotic-early primary myelofibrosis in Chinese patients. Hum Pathol 45:498–503. https://doi.org/10.1016/j.humpath.2013.08.021 CrossRefPubMed

11.

Pizzi M, Silver RT, Barel A, Orazi A (2015) Recombinant interferon-alpha in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol 28:1315–1323. https://doi.org/10.1038/modpathol.2015.93 CrossRefPubMed

12.

Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S (2014) Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med 7:89–101. https://doi.org/10.2147/IJGM.S51800 CrossRefPubMedPubMedCentral

13.

Cazzola M, Kralovics R (2014) From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 123:3714–3719. https://doi.org/10.1182/blood-2014-03-530865 CrossRefPubMed

14.

Tefferi A (2016) Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 91:1262–1271. https://doi.org/10.1002/ajh.24592 CrossRefPubMed

15.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270. https://doi.org/10.1371/journal.pmed.0030270 CrossRefPubMedPubMedCentral

16.

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379–2390. https://doi.org/10.1056/NEJMoa1311347 CrossRefPubMed

17.

Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391–2405. https://doi.org/10.1056/NEJMoa1312542 CrossRefPubMedPubMedCentral

18.

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M, on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators (2014) Clinical effect of driver mutations of JAK2, CALR or MPL in primary myelofibrosis. Blood 124:1062–1069. https://doi.org/10.1182/blood-2014-05-578435 CrossRefPubMedPubMedCentral

19.

Tefferi A, Lasho TL, Finke C, Belachew AA, Wassie EA, Ketterling RP, Hanson CA, Pardanani A (2014) Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia 28:1568–1570. https://doi.org/10.1038/leu.2014.83 CrossRefPubMed

20.

Tefferi A, Lasho TL, Tischer A, Wassie EA, Finke CM, Belachew AA, Ketterling RP, Hanson CA, Pardanani AD (2014) The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 124:2465–2466. https://doi.org/10.1182/blood-2014-07-588426 CrossRefPubMedPubMedCentral

21.

Guglielmelli P, Rotunno G, Fanelli T, Pacilli A, Brogi G, Calabresi L, Pancrazzi A, Vannucchi AM (2015) Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer J 5:e360. https://doi.org/10.1038/bcj.2015.90 CrossRefPubMedPubMedCentral

22.

Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28:1472–1477. https://doi.org/10.1038/leu.2014.3 CrossRefPubMed

23.

Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NCP, Tefferi A (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27:1861–1869. https://doi.org/10.1038/leu.2013.119 CrossRefPubMed

24.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32:1057–1069. https://doi.org/10.1038/s41375-018-0077-1 CrossRefPubMedPubMedCentral

25.

National Comprehensive Cancer Network (2016) NCCN Guidelines. Myeloproliferative Neoplasms Version 2.2017. https://www.nccn org/professionals/physician_gls/pdf/mpn pdf: Accessed November 11, 2016

26.

Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N, Thiele J, Buske C, Guidelines Committee ESMO (2015) Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v85–v99. https://doi.org/10.1093/annonc/mdv203 CrossRefPubMed

27.

Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G (2015) Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN International Working Group. Leukemia 29:2126–2133. https://doi.org/10.1038/leu.2015.233 CrossRefPubMed

28.

Kröger N, Giorgino T, Scott BL et al (2015) Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 125:3347–3350; quiz 3364. https://doi.org/10.1182/blood-2014-10-608315 CrossRefPubMedPubMedCentral

29.

Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka HM, MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (2007) Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 35:1719–1722. https://doi.org/10.1016/j.exphem.2007.08.022 CrossRefPubMed

30.

Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuk F, von Hünerbein N, Kvasnicka HM, Thiele J, Kreipe HH, Büsche G (2014) Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant 20:812–815. https://doi.org/10.1016/j.bbmt.2014.02.019 CrossRefPubMed

31.

Gupta V, Gotlib J, Radich JP, Kröger NM, Rondelli D, Verstovsek S, Deeg HJ (2014) Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant 20:1274–1281. https://doi.org/10.1016/j.bbmt.2014.03.017 CrossRefPubMedPubMedCentral

32.

Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kröger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M (2010) Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16:358–367. https://doi.org/10.1016/j.bbmt.2009.10.025 CrossRefPubMed

33.

Martínez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Díaz-Beyá M, Cervantes F (2010) Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 89:1233–1237. https://doi.org/10.1007/s00277-010-1019-9 CrossRefPubMed

34.

Kiladjian JJ (2015) Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms. Am Soc Clin Oncol Educ Book e389–96. https://doi.org/10.14694/EdBook_AM.2015.35.e389

35.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807. https://doi.org/10.1056/NEJMoa1110557 CrossRefPubMedPubMedCentral

36.

Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798. https://doi.org/10.1056/NEJMoa1110556 CrossRefPubMed

37.

Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S (2013) Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 31:1285–1292. https://doi.org/10.1200/JCO.2012.44.4489 CrossRefPubMedPubMedCentral

38.

Harrison CN, Mesa RA, Kiladjian JJ, al-Ali HK, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM (2013) Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol 162:229–239. https://doi.org/10.1111/bjh.12375 CrossRefPubMed

39.

Cervantes F, Pereira A (2017) Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood 129:832–837. https://doi.org/10.1182/blood-2016-11-731604 CrossRefPubMed

40.

Sever M, Newberry KJ, Verstovsek S (2014) Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leuk Lymphoma 55:2685–2690. https://doi.org/10.3109/10428194.2014.893310 CrossRefPubMedPubMedCentral

41.

Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128–1132PubMed

42.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ESG, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29:3179–3184. https://doi.org/10.1200/JCO.2010.34.5298 CrossRefPubMed

43.

Hernández-Boluda JC, Pereira A, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Pérez-Encinas M, Estrada N, Velez P, Fox ML, García-Gutiérrez V, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Gómez M, Cervantes F (2018) Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia 32:553–555. https://doi.org/10.1038/leu.2017.297 CrossRefPubMed

44.

Geyer HL, Emanuel RM, Dueck AC et al (2014) Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood 123:1803–3810. https://doi.org/10.1182/blood-2013-09-527903 CrossRef

45.

Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A, Biamonte F, Pardanani A, Zoi K, Reiter A, Duncombe A, Fanelli T, Pietra D, Rumi E, Finke C, Gangat N, Ketterling RP, Knudson RA, Hanson CA, Bosi A, Pereira A, Manfredini R, Cervantes F, Barosi G, Cazzola M, Cross NCP, Vannucchi AM, Tefferi A (2014) The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 28:1804–1810. https://doi.org/10.1038/leu.2014.76 CrossRefPubMed

46.

Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, Brogi G, Fanelli T, Pancrazzi A, Pietra D, Bernardis I, Belotti C, Pieri L, Sant'Antonio E, Salmoiraghi S, Cilloni D, Rambaldi A, Passamonti F, Barbui T, Manfredini R, Cazzola M, Tagliafico E, Vannucchi AM, Guglielmelli P (2016) Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM Group. Am J Hematol 91:681–686. https://doi.org/10.1002/ajh.24377 CrossRefPubMed

47.

Tefferi A, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A (2017) Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. Br J Haematol. https://doi.org/10.1111/bjh.15010

48.

Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN landmark survey. BMC Cancer 16:167. https://doi.org/10.1186/s12885-016-2208-2 CrossRefPubMedPubMedCentral

49.

Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol 96:1653–1665. https://doi.org/10.1007/s00277-017-3082-y CrossRefPubMedPubMedCentral

50.

Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, al-Kali A, Ketterling RP, Hanson CA, Pardanani A (2012) One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 87:25–33. https://doi.org/10.1016/j.mayocp.2011.11.001 CrossRefPubMedPubMedCentral

51.

Guglielmelli P, Rotunno G, Pacilli A et al (2016) Differences in clinical and molecular characteristics and outcome in prefibrotic and overt primary myelofibrosis according to 2016 WHO criteria. A study on 639 patients of the AGIMM Group. Blood 128:abstract 943

52.

Harrison CN, Vannucchi AM, Kiladjian JJ et al (2015) Long-term efficacy and safety in COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis: 5-year final study results. Blood 126:abstract 59

53.

Verstovsek S, Mesa RA, Gotlib J et al (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10:55. https://doi.org/10.1186/s13045-017-0417-z CrossRefPubMedPubMedCentral

54.

Verstovsek S, Gupta V, Gotlib JR et al (2016) A pooled overall survival (OS) analysis of 5-year data from the COMFORT-I and COMFORT-II trials of ruxolitinib for the treatment of myelofibrosis (MF). Blood 128:abstract 3110

55.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98:1865–1871. https://doi.org/10.3324/haematol.2013.092155 CrossRefPubMedPubMedCentral

56.

Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S, on behalf of the COMFORT Investigators (2015) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100:1139–1145. https://doi.org/10.3324/haematol.2014.119545 CrossRefPubMedPubMedCentral

57.

Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, Knoops L, Kiladjian JJ, Mora B, Hollaender N, Pascutto C, Harrison C, Cazzola M (2014) Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 123:1833–1835. https://doi.org/10.1182/blood-2013-12-544411 CrossRefPubMed

58.

Mesa RA, Gotlib J, Kantarjian H, Sun W, Verstovsek S (2012) Clinical benefits of ruxolitinib therapy in myelofibrosis patients with varying degrees of splenomegaly and symptoms. Poster presented at: 2012 American Society of Hematology Annual Meeting and Exposition; Atlanta, GA

59.

Palandri F, Palumbo GA, Bonifacio M et al (2016) Predictors for response to ruxolitinib in real-life: an observational independent study on 408 patients with myelofibrosis. Blood 128:abstract 1128

60.

Kvasnicka HM, Thiele J, Bueso-Ramos C, Hou K, Cortes J, Kantarjian H, Verstovsek S (2013) Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. J Clin Oncol 31:abstract 7030

61.

Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, Verstovsek S (2013) Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 122:abstract 4055

62.

Wilkins BS, Radia D, Woodley C, El Farhi S, Keohane C, Harrison CN (2013) Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitortreatment with ruxolitinib. Haematologica 98:1872–1876. https://doi.org/10.3324/haematol.2013.095109 CrossRefPubMedPubMedCentral

63.

Harrison CN, Vannucchi AM, Kiladjian J-J et al (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30:1701–1707. https://doi.org/10.1038/leu.2016.148 CrossRefPubMedPubMedCentral

64.

Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Dawson MK, Harrison C (2015) Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST trial. Br J Haematol 170:29–39. https://doi.org/10.1111/bjh.13379 CrossRefPubMed

65.

Passamonti F, Gupta V, Martino B, et al (2017) Comparing the safety and efficacy of ruxolitinib (RUX) in patients (PTS) with DIPSS low/intermediate-1–, intermediate-2–, and high-risk myelofibrosis (MF) in JUMP, a phase 3B, expanded-access study. EHA annual meeting; June 22-25, 2017; Madrid, Spain [abstract E1333]

66.

Al-Ali HK, Griesshammer M, le Coutre P et al (2016) Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica 101:1065–1073. https://doi.org/10.3324/haematol.2016.143677 CrossRefPubMedPubMedCentral

67.

Davis KL, Cote I, Kaye JA, Mendelson E, Goa H, Perez Ronco J (2015) Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol 2015:848473. https://doi.org/10.1155/2015/848473 CrossRefPubMedPubMedCentral

68.

Palandri F, Tiribelli M, Benevolo G et al (2017) Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: results from an independent study. Hematol Oncol 36:285–290. https://doi.org/10.1002/hon.2429 CrossRefPubMed

69.

Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, Martinelli G, Lewis RE, Vianelli N, Cavo M, Palandri F (2017) Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol 92:37–41. https://doi.org/10.1002/ajh.24572 CrossRefPubMed

70.

Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F (2018) Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients. Hematol Oncol [Epub ahead of print] 36:561–569. https://doi.org/10.1002/hon.2509 CrossRef

71.

Kiladjian J-J, Verstovsek S, Griesshammer M et al (2017) Results from the 208-week (4-year) follow-up of RESPONSE trial, a phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of polycythemia vera (PV). Blood 130:abstract 322

72.

Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F (2018) Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol 97:1591–1600. https://doi.org/10.1007/s00277-018-3365-y CrossRefPubMedPubMedCentral

73.

Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Schoenwald M, Andreoli A, Abgrall JF, Kiladjian JJ (2013) Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French Cooperative Groups. Br J Haematol 162:783–791. https://doi.org/10.1111/bjh.12459 CrossRefPubMed

74.

Gowin K, Thapaliya P, Samuelson J, Harrison C, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J, Gentry A, Kiladjian JJ, O'Connell C, Mesa R (2012) Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 97:1570–1573. https://doi.org/10.3324/haematol.2011.061390 CrossRefPubMedPubMedCentral

75.

Silver RT, Barel A, Lascu E, Ritchie EK, Roboz GJ, Christos P, Orazi A, Hassane DC, Tam W, Cross NCP (2016) The effect of initial molecular profile on response to recombinant interferon alpha (rIFNα) treatment in early myelofibrosis. Blood 128:abstract 944

76.

O'Neill C, Siddiqi I, Brynes RK, Vergara-Lluri M, Moschiano E, O'Connell C (2016) Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy. Ann Hematol 95:733–738. https://doi.org/10.1007/s00277-016-2631-0 CrossRefPubMed

77.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H, For the COMFORT-I investigators (2015) Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100:479–488. https://doi.org/10.3324/haematol.2014.115840 CrossRefPubMedPubMedCentral

Title: Treating early-stage myelofibrosis
Authors: Francesca Palandri
Elena Sabattini
Margherita Maffioli
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 2/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3526-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

Prognostic significance of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in diffuse large B cell lymphoma

Associations of complementation group, ALDH2 genotype, and clonal abnormalities with hematological outcome in Japanese patients with Fanconi anemia

Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors

Genetic determinants related to pharmacological induction of foetal haemoglobin in transfusion-dependent HbE-β thalassaemia

Autoimmune disease-associated non-Hodgkin’s lymphoma—a large retrospective study from China

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials